The first-in-human trial showed that the Ad5 vectored Covid-19 vaccine was tolerable and immunogenic in healthy adults.
The Philippines is expected to take part in the clinical trials for coronavirus vaccine by the last quarter of the year, said Presidential Spokesperson Harry Roque on Sunday. A highly effective vaccine could be tested in as little as six months if there is a big difference in benefit between the vaccine and placebo groups, Corey said.
It has also been observed that in China, where the trial is going on, people who had Ad5 antibodies were less likely to develop a strong immune response to the vaccine.
According to the Director of the Thai University test developed from COVID-19 vaccine in experimental animals have demonstrated an excellent result, but in order to be able to use the drug on a population, it must go through a full cycle of testing involving human volunteers.
The data presented is encouraging, but there are several concerning warning signs that hurdles may lie ahead.
One person in the high dose group experienced severe fatigue, breathing difficulties and muscle pain.
"The challenges in the development of a Covid-19 vaccine are unprecedented, and the ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from Covid-19". "This result shows a promising vision for the development of COVID-19 vaccines, but we are still a long way from this vaccine being available to all".
In addition, the Philippines will also participate in trials held by two Chinese organizations: The Guangzhou Institutes of Biomedicine and Health and the China National Pharmaceutical Group's Wuhan and Beijing institutes of biological products. Researchers will closely be assessing the immune response to the vaccine on these volunteers.
However, they said high pre-existing immunity to adenovirus type 5 - the common cold virus vector used in the study, may have reduced both the antibody and T-cell response in the participants. Speaking to STATNews, Michael Mina from Harvard's T.H. Chan School of Public Health, says this is a common problem with vaccines using this kind of adenovirus delivery system.
Citing the main limitations of the trial, the authors said the study had a small sample size and was conducted in relatively short duration, with a lack of randomised control group.
The Oxford vaccine is one of four worldwide that are now being worked on in order to find a solution against COVID-19. The scientists are not planning to deliberately infect volunteers with the virus to test the vaccine, so instead, they require relatively high rates of the virus to be spreading through the community to evaluate success.
But results were only from a handful of patients, and at the time that Moderna published results only four were confirmed as producing antibodies capable of neutralising the virus. We said earlier in the year that there was an 80% chance of developing an effective vaccine by September.
"We're in the freaky position of wanting Covid to stay, at least for a little while".
Del Rio, a professor of medicine at Emory University, is one of the researchers testing the efficacy of a vaccine at the Atlanta college's Vaccine and Treatment Evaluation Unit developed by the MA biotech firm Moderna in cooperation with the National Institutes of Health.